1. Home
  2. LADR vs PCRX Comparison

LADR vs PCRX Comparison

Compare LADR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LADR
  • PCRX
  • Stock Information
  • Founded
  • LADR 2008
  • PCRX 2006
  • Country
  • LADR United States
  • PCRX United States
  • Employees
  • LADR N/A
  • PCRX N/A
  • Industry
  • LADR Real Estate Investment Trusts
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LADR Real Estate
  • PCRX Health Care
  • Exchange
  • LADR Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • LADR 1.4B
  • PCRX 1.2B
  • IPO Year
  • LADR 2014
  • PCRX 2011
  • Fundamental
  • Price
  • LADR $10.98
  • PCRX $22.54
  • Analyst Decision
  • LADR Buy
  • PCRX Buy
  • Analyst Count
  • LADR 4
  • PCRX 7
  • Target Price
  • LADR $13.13
  • PCRX $27.14
  • AVG Volume (30 Days)
  • LADR 870.3K
  • PCRX 651.4K
  • Earning Date
  • LADR 07-24-2025
  • PCRX 08-05-2025
  • Dividend Yield
  • LADR 8.39%
  • PCRX N/A
  • EPS Growth
  • LADR N/A
  • PCRX N/A
  • EPS
  • LADR 0.70
  • PCRX N/A
  • Revenue
  • LADR $243,794,000.00
  • PCRX $702,772,000.00
  • Revenue This Year
  • LADR N/A
  • PCRX $7.90
  • Revenue Next Year
  • LADR $17.60
  • PCRX $11.02
  • P/E Ratio
  • LADR $15.68
  • PCRX N/A
  • Revenue Growth
  • LADR N/A
  • PCRX 3.08
  • 52 Week Low
  • LADR $9.68
  • PCRX $11.16
  • 52 Week High
  • LADR $12.36
  • PCRX $27.64
  • Technical
  • Relative Strength Index (RSI)
  • LADR 50.03
  • PCRX 48.56
  • Support Level
  • LADR $10.81
  • PCRX $20.85
  • Resistance Level
  • LADR $11.18
  • PCRX $23.27
  • Average True Range (ATR)
  • LADR 0.18
  • PCRX 0.90
  • MACD
  • LADR -0.03
  • PCRX 0.13
  • Stochastic Oscillator
  • LADR 26.15
  • PCRX 69.83

About LADR Ladder Capital Corp

Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: